Antengene's Innovative Breakthroughs in ADC and TCE Technologies
SHANGHAI and HONG KONG - Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a prominent global biotech company, shared groundbreaking updates at the recent Annual J.P. Morgan Healthcare Conference held in San Francisco. Arriving at the forefront of innovation, Antengene highlighted the impressive clinical data surrounding its leading clinical asset, ATG-022, which is a CLDN18.2 antibody-drug conjugate (ADC). Furthermore, they showcased the research and development trajectory for ATG-125, a bispecific ADC targeting B7-H3 and PD-L1, as well as their proprietary T cell engager (TCE) platform, AnTenGager™.
Core Clinical Program: ATG-022
ATG-022 has demonstrated compelling outcomes from the Phase I/II CLINCH study. As of late December 2025, results indicated a significant objective response rate (ORR) of 40% among patients with moderate to high CLDN18.2 expression when treated in the 2.4 mg/kg dose cohort. Notably, for the 1.8 mg/kg cohort, the ORR rose to 46.7%, underlining the treatment's potential efficacy. Data also revealed a high disease control rate (DCR), showcasing the robustness of ATG-022 across multiple expression levels.
These findings, including a median progression-free survival (mPFS) of 6.97 months and impressive median overall survival (mOS) figures, highlight ATG-022’s promise. Beyond gastric cancer, early indications suggest effectiveness in treating non-gastrointestinal tumors, paving the way for expanding the patient population.
Promising Frontline Combination Potential
With encouraging results from frontline combination treatments, ATG-022’s profile stands out due to a favorable safety margin. The incidents of Grade 3 or higher treatment-related adverse events (TRAEs) stayed relatively low at 19.4%. This positions ATG-022 as not only a leading ADC but also as a potential partner in combination therapies with existing standards of care.
Advancing Clinical Development
Ongoing studies, such as the Phase Ib/II CLINCH-2 study, further cement Antengene’s commitment to the diverse applications of ATG-022 across several stages of gastric cancer treatment. The expansive efforts, including various dosing strategies and exploration of multiple tumor types, underscore Antengene's focus on impactful oncology solutions.
Next-Generation ADCs and Proprietary TCEs
ATG-125 represents a dual-function molecule under development, strategically designed to engage the immune system while delivering direct cytotoxic actions. By inhibiting crucial immunosuppressive signals, ATG-125 holds promise for enhancing T cell activation, as shown in preclinical studies that point toward superior efficacy over traditional approaches.
AnTenGager™ T Cell Engager Platform
This innovative platform features advanced capabilities for effectively targeting low-expressing cancer cells, showcasing broad applications not only in solid tumors but also in various autoimmune conditions. Notable investigational agents include ATG-201 for B cell targeting and ATG-106 for ovarian and kidney cancers, each demonstrating Antengene’s rigorous dedication to addressing significant medical needs.
Innovative Treatment for Autoimmune Diseases
In addition to oncology, Antengene is introducing ATG-207, aimed at treating T cell-mediated autoimmune diseases. Scheduled to present additional preclinical findings, Antengene's forward-looking strategies highlight their commitment to pushing boundaries within biotech and enhancing patient care worldwide.
About Antengene
Antengene Corporation Limited is an R&D-driven biotech company focused on creating first-in-class therapeutics for diseases lacking effective treatments. Their extensive pipeline includes therapies addressing major health issues, with several programs currently in different stages of clinical development. Current highlights include favorable results from ATG-022 and innovative developments in T cell engagery technology.
Frequently Asked Questions
1. What is Antengene Corporation's main focus?
Antengene is dedicated to developing innovative therapies for autoimmune diseases and cancers, emphasizing best-in-class treatments.
2. What are the highlights of ATG-022?
ATG-022 has shown strong clinical data, including significant response rates and potential effectiveness across various tumor types.
3. How does ATG-125 differ from traditional ADCs?
ATG-125 combines direct cytotoxicity with immune activation, enhancing overall treatment efficacy against cancer.
4. What future plans does Antengene have for its TCE platform?
Antengene plans to advance multiple TCE programs targeting various cancers and autoimmune diseases, including upcoming IND submissions.
5. Where can I find more information about Antengene?
For further details, you may visit Antengene's corporate website or their recent presentations at industry conferences.
